GlassScriptPhysician profile
Madhuri Yalamanchili
NPI 1528057189
$20,878.60
in general payments reported to CMS, 2019-2025
84 companies · $4,734 in 2025
The $4,734 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,596 · 2020: $463 · 2021: $1,113 · 2022: $2,698 · 2023: $6,173 · 2024: $4,102 · 2025: $4,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,634 · Consulting Fee: $2,700 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,215 · Travel and Lodging: $1,142 · Education: $297 · Gift: $20.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,634.20 |
| Consulting Fee | $2,700.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,215.00 |
| Travel and Lodging | $1,141.78 |
| Education | $297.37 |
| Gift | $20.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $2,183.68 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| US Oncology Corporate, INC. | $1,794.15 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $1,527.17 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| Genmab U.S., INC. | $1,269.53 | 2023-2024 | Epkinly, Tivdak |
| Pfizer INC. | $1,106.15 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,047.63 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $944.24 | 2019-2025 | Opdivo, Eliquis, Opdualag |
| Abbvie INC. | $760.15 | 2019-2025 | Venclexta |
| Celgene Corporation | $712.74 | 2020-2025 | Opdivo, Pomalyst, Reblozyl |
| Janssen Biotech, INC. | $708.14 | 2019-2024 | Darzalex, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $621.50 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Genentech USA, INC. | $526.89 | 2019-2025 | Polivy, Perjeta, Phesgo |
| Genzyme Corporation | $503.42 | 2020-2025 | |
| Glaxosmithkline, LLC. | $346.52 | 2019-2025 | Zejula, Jemperli, Ojjaara |
| Pharmaessentia USA Corporation | $329.28 | 2022-2025 | Besremi |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $322.72 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Seagen INC. | $320.31 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Gilead Sciences, INC. | $311.31 | 2021-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $270.24 | 2021-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Eisai INC. | $250.62 | 2019-2025 | |
| Daiichi Sankyo INC. | $236.90 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Amgen INC. | $227.95 | 2020-2023 | Kyprolis, Lumakras, Blincyto |
| Emd Serono, INC. | $214.20 | 2019-2025 | Bavencio |
| Epizyme, INC. | $200.09 | 2021-2022 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Astellas Pharma US INC | $188.61 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Pharmacyclics LLC, An Abbvie Company | $162.68 | 2020-2023 | Imbruvica, Epkinly |
| Kite Pharma, INC. | $157.60 | 2021-2025 | Yescarta |
| Jazz Pharmaceuticals INC. | $155.23 | 2019-2025 | |
| Deciphera Pharmaceuticals INC. | $143.28 | 2021-2025 | Qinlock |
| Myriad Genetic Laboratories, INC. | $142.90 | 2023-2025 | Precisetumor, Myrisk |
| Lilly USA, LLC | $139.26 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Karyopharm Therapeutics INC. | $138.64 | 2020-2024 | Xpovio |
| Immunocore Limited | $138.12 | 2024 | Kimmtrak |
| Alexion Pharmaceuticals, INC. | $126.55 | 2019-2025 | Ultomiris |
| Clovis Oncology, INC. | $122.19 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $119.41 | 2023-2024 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $112.61 | 2021-2024 | |
| Puma Biotechnology, INC. | $111.72 | 2021-2023 | |
| Beigene USA, INC. | $103.71 | 2022-2024 | Brukinsa |
| Servier Pharmaceuticals LLC | $103.05 | 2023-2025 | |
| Acrotech Biopharma INC. | $97.22 | 2022-2024 | Beleodaq |
| Blueprint Medicines Corporation | $89.92 | 2021-2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $85.95 | 2023 | |
| Sobi, INC | $80.14 | 2022-2025 | |
| Exelixis INC. | $78.66 | 2020-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $78.40 | 2019-2025 | |
| Adc Therapeutics America, INC. | $74.29 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $65.54 | 2021-2024 | Onivyde |
| Apellis Pharmaceuticals, INC. | $64.09 | 2023 | Empaveli |
| Pharmacosmos Therapeutics INC. | $62.31 | 2022-2023 | Monoferric |
| Beone Medicines USA, INC. | $58.64 | 2025 | Tevimbra, Brukinsa |
| Kyowa Kirin, INC. | $53.58 | 2022-2024 | Poteligeo |
| Regeneron Healthcare Solutions, INC. | $51.62 | 2022-2025 | Lynozyfic |
| Sun Pharmaceutical Industries INC. | $51.20 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $49.54 | 2019-2024 | |
| Global Blood Therapeutics, INC. | $48.52 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $46.41 | 2019-2020 | |
| Morphosys, US INC. | $45.79 | 2021-2023 | Monjuvi |
| Tersera Therapeutics LLC | $40.99 | 2022-2023 | Xermelo |
| Eagle Pharmaceuticals, INC. | $39.49 | 2023 | |
| Alnylam Pharmaceuticals INC. | $37.14 | 2024 | Givlaari |
| Fresenius Kabi USA, LLC | $34.25 | 2022 | |
| G1 Therapeutics, INC. | $33.01 | 2022 | |
| Stemline Therapeutics INC. | $32.99 | 2023-2024 | Orserdu |
| Immunogen, INC. | $31.59 | 2023-2024 | Elahere, Elahere |
| Eusa Pharma (US) LLC | $27.65 | 2021 | |
| Dova Pharmaceuticals | $26.91 | 2019-2021 | |
| Cti Biopharma Corp. | $23.61 | 2023 | Vonjo |
| Tolmar Pharmaceuticals, INC. | $23.18 | 2022 | |
| Legend Biotech USA INC. | $21.41 | 2025 | Carvykti |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Springworks Therapeutics, INC. | $20.98 | 2024 | Ogsiveo |
| Nuvation Bio INC. | $20.58 | 2025 | Ibtrozi |
| Recordati_rare_diseases_inc. | $19.44 | 2025 | Sylvant |
| Spectrum Pharmaceuticals INC. | $18.16 | 2023 | Rolvedon |
| Janssen Scientific Affairs, LLC | $17.93 | 2022 | |
| Nestle Healthcare Nutrition INC. | $17.49 | 2021 | |
| Tempus Ai, INC | $17.14 | 2025 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $14.69 | 2024 | Tavalisse, Rezlidhia |
| Iovance Biotherapeutics, INC. | $14.56 | 2025 | Amtagvi |
| Novocure INC. | $14.18 | 2025 | Optune Gio |
| Advanced Accelerator Applications | $14.17 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhuri Yalamanchili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.